Companies / Avalyn Pharma Inc.
Avalyn Pharma Inc.
Nasdaq: AVLNCIK 1540171BOSTON, MA
Ownership
44.3M shares outstanding · as of Aug 31, 2026
Ownership
| 10%+ / strategic | 8.76% | 3,883,289 |
| Institutions | 7.36% | 3,264,665 |
| Public float | 83.88% | 37,185,141 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 1
View all →| Insider | % of shares | Shares |
|---|---|---|
Novo Holdings A/S10% owner | 8.76% | 3,883,289 |
Institutional holders 4
View all →| Holder | Value | % of shares |
|---|---|---|
| $74.68M | 5.12% | |
| $32.17M | 2.20% | |
| $557.4K | 0.04% | |
| $67.9K | <0.01% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | NVP Associates, LLC 13F manager | New | Common stock | $74.68M | +2.3M | 2,268,404 5.12% of shares | high |
| Q2 2026 as of | BlackRock, Inc. 13F manager | New | Common stock | $32.17M | +977K | 977,264 2.20% of shares | medium |
| Q2 2026 as of | Deutsche Bank AG 13F manager | New | Common stock | $557.4K | +17K | 16,933 0.04% of shares | low |
| Q2 2026 as of | Persistent Asset Partners Ltd 13F manager | New | Common stock | $67.9K | +2K | 2,064 <0.01% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Perceptive Advisors LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| AVLN | — | 05348Y105 |